Ardelyx (ARDX) Receives News Sentiment Rating of 0.08
News articles about Ardelyx (NASDAQ:ARDX) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ardelyx earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.4675458694676 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Ardelyx, Inc. (NASDAQ:ARDX) Moving Today – Up $0.30 – First News 24 (firstnewspaper24.com)
- Ardelyx, Inc. (NASDAQ:ARDX) Stock Traded 10.2% Above Its 50 Day Average – First News 24 (firstnewspaper24.com)
- Analysts Expect Ardelyx, Inc. (ARDX) to Announce -$0.56 Earnings Per Share (americanbankingnews.com)
- Financial Analysis: Ardelyx (ARDX) and NeuroDerm (NDRM) (americanbankingnews.com)
- Ardelyx, Inc. (ARDX) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
Shares of Ardelyx (NASDAQ:ARDX) opened at 5.60 on Friday. Ardelyx has a 52-week low of $4.05 and a 52-week high of $16.30. The firm has a 50-day moving average of $5.08 and a 200 day moving average of $7.94. The stock’s market capitalization is $265.69 million.
Ardelyx (NASDAQ:ARDX) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.09. Equities research analysts forecast that Ardelyx will post ($2.19) EPS for the current fiscal year.
A number of research firms recently commented on ARDX. Cantor Fitzgerald set a $12.00 price target on shares of Ardelyx and gave the stock a “buy” rating in a research note on Wednesday, August 9th. BidaskClub raised shares of Ardelyx from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. ValuEngine raised shares of Ardelyx from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 6th. Finally, Zacks Investment Research cut shares of Ardelyx from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $14.13.
ILLEGAL ACTIVITY NOTICE: “Ardelyx (ARDX) Receives News Sentiment Rating of 0.08” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/01/ardelyx-ardx-receives-news-sentiment-rating-of-0-08.html.
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Stock Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related stocks with our FREE daily email newsletter.